Christopher E Woods, MD
Cardiac Electrophysiology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Woods’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A100919 · Current
Licensed to practise in California · since 2007 · expires 2027-06-30 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$240,322
Medicare paid this office $240,322 for 449 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 85 | $67,006 | $770 |
| New patient visit (60+ min) | 134 | $25,338 | $189 |
| Insertion of tube in upper and/or lower heart chambers to record and identify origin of abnormal heart rhythm | 97 | $23,002 | $226 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 19 | $13,803 | $690 |
| Long return visit (40+ min) | 65 | $10,560 | $160 |
See all 21 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 85 | $67,006 | $770 |
| New patient visit (60+ min) | 134 | $25,338 | $189 |
| Insertion of tube in upper and/or lower heart chambers to record and identify origin of abnormal heart rhythm | 97 | $23,002 | $226 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 19 | $13,803 | $690 |
| Long return visit (40+ min) | 65 | $10,560 | $160 |
| Return visit (30+ min) | 86 | $10,063 | $106 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 35 | $9,857 | $253 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 27 | $6,836 | $253 |
| Programming of heart rhythm stimulation after drug infusion | 106 | $6,695 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 230 | $5,668 | $13 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 71 | $4,399 | $20 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,293 | $153 |
| New patient visit (45+ min) | 33 | $3,882 | $118 |
| Critical care, first 30-74 minutes | 15 | $3,268 | $182 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 35 | $2,941 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 35 | $2,560 | $23 |
| Insertion of catheters for recording and pacing of left lower heart chamber rhythm and induction of abnormal rhythm | 15 | $2,110 | $141 |
| Insertion of tube in left heart chamber through heart septum | 11 | $1,887 | $172 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 19 | $1,194 | $63 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 26 | $587 | $23 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 23 | $469 | $20 |
Procedures Medicare counted
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
449 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 11% · Women 37% · Also on Medicaid 15% · Health risk score 1.65. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 1.8.
Conditions among them: High blood pressure 75% · Atrial fibrillation 75% · Coronary heart disease 47% · Heart failure 47% · Chronic kidney disease 32% · Diabetes 27% · Depression 16% · Cancer 14% · COPD 12% · Stroke 8% · Dementia 4%.
The office billed $1,363,787, Medicare allowed $310,192 and paid $240,322; for 1,900 services of 53 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 449 | 1,900 | 75 | 1.65 | $1,363,787 | $240,322 |
| 2023 | 458 | 1,580 | 76 | 1.60 | $1,251,908 | $237,475 |
| 2022 | 536 | 1,754 | 77 | 1.60 | $1,327,031 | $280,832 |
| 2021 | 835 | 3,140 | 78 | 1.53 | $1,392,963 | $345,415 |
| 2020 | 857 | 2,566 | 77 | 1.65 | $854,453 | $214,195 |
| 2019 | 1,006 | 2,743 | 77 | 1.63 | $1,147,529 | $270,049 |
| 2018 | 823 | 2,512 | 77 | 1.73 | $1,044,110 | $263,611 |
| 2017 | 481 | 1,742 | 76 | 1.67 | $854,506 | $226,406 |
| 2016 | 481 | 1,940 | 76 | 1.75 | $941,860 | $250,083 |
| 2015 | 491 | 1,887 | 76 | 1.75 | $1,005,103 | $276,569 |
| 2014 | 156 | 421 | 77 | 1.56 | $201,777 | $52,383 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 72 | $58,507 | $813 |
| New patient visit (45+ min) | 131 | $18,055 | $138 |
| Insertion of tube in upper and/or lower heart chambers to record and identify origin of abnormal heart rhythm | 75 | $17,816 | $238 |
| Return visit (30+ min) | 122 | $14,876 | $109 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 11 | $11,270 | $867 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 37 | $10,578 | $264 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 34 | $9,785 | $264 |
| Critical care, first 30-74 minutes | 28 | $8,694 | $189 |
| New patient visit (60+ min) | 46 | $8,622 | $187 |
| Long return visit (40+ min) | 54 | $8,036 | $146 |
| Repair of left upper heart chamber with implant with review by radiologist | 17 | $7,104 | $418 |
| Programming of heart rhythm stimulation after drug infusion | 83 | $6,682 | $79 |
| Insertion of catheters for recording and pacing of left lower heart chamber rhythm and induction of abnormal rhythm | 45 | $6,610 | $147 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,325 | $444 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 166 | $3,679 | $14 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,265 | $155 |
| Short return visit (20+ min) | 38 | $2,676 | $70 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 49 | $1,907 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,619 | $108 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 29 | $1,560 | $29 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 14 | $1,229 | $68 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 39 | $895 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 22 | $840 | $25 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 19 | $447 | $24 |
2022: 33 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 74 | $72,779 | $958 |
| New patient visit (60+ min) | 98 | $18,536 | $189 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 49 | $15,037 | $269 |
| Insertion of tube in upper and/or lower heart chambers to record and identify origin of abnormal heart rhythm | 56 | $13,951 | $241 |
| Return visit (30+ min) | 120 | $13,780 | $104 |
| Long return visit (40+ min) | 84 | $13,017 | $148 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 14 | $12,648 | $903 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 35 | $10,714 | $268 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 14 | $10,064 | $719 |
| New patient visit (45+ min) | 62 | $9,506 | $153 |
| Critical care, first 30-74 minutes | 37 | $9,432 | $185 |
| Programming of heart rhythm stimulation after drug infusion | 91 | $9,340 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,201 | $171 |
| Insertion of catheters for recording and pacing of left lower heart chamber rhythm and induction of abnormal rhythm | 43 | $6,410 | $149 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,840 | $440 |
| Interpretation and report of ultrasound of heart | 40 | $3,200 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $3,053 | $93 |
| Insertion of tube in left heart chamber through heart septum | 13 | $2,348 | $181 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $1,896 | $79 |
| External shock to heart to regulate heart beat | 19 | $1,885 | $94 |
| Short return visit (20+ min) | 21 | $1,707 | $81 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 18 | $1,569 | $87 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 100 | $1,449 | $14 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 83 | $1,361 | $15 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 35 | $949 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 49 | $690 | $13 |
| Ultrasound of heart, follow-up | 28 | $661 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 64 | $632 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 38 | $621 | $16 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 11 | $248 | $23 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $184 | $13 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 11 | $165 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 41 | $119 | $3 |
2021: 35 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 74 | $72,868 | $946 |
| New patient visit (60+ min) | 118 | $23,341 | $198 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 85 | $22,155 | $252 |
| Return visit (30+ min) | 186 | $21,830 | $106 |
| Long return visit (40+ min) | 110 | $21,718 | $156 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 43 | $18,621 | $351 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 18 | $17,456 | $919 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 35 | $13,188 | $366 |
| Programming of heart rhythm stimulation after drug infusion | 98 | $12,501 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,450 | $175 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 164 | $9,629 | $25 |
| Critical care, first 30-74 minutes | 30 | $9,465 | $182 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 12 | $8,106 | $675 |
| Telephone medical discussion with physician, 21-30 minutes | 76 | $7,707 | $91 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 112 | $6,418 | $25 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 189 | $4,688 | $24 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 52 | $3,905 | $31 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 32 | $3,601 | $109 |
| External shock to heart to regulate heart beat | 26 | $3,109 | $97 |
| Ultrasound of heart with probe in esophagus, with report | 31 | $3,054 | $99 |
| Heart rhythm recording of continous external ekg over 8-15 days | 186 | $2,984 | $16 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 28 | $2,813 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,792 | $93 |
| Insertion of tube in left heart chamber through heart septum | 12 | $2,384 | $183 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 35 | $2,180 | $24 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 35 | $2,081 | $23 |
| Programming of dual lead pacemaker system | 24 | $1,735 | $72 |
| Ultrasound of heart, follow-up | 65 | $1,540 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 92 | $1,312 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 106 | $1,060 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 16 | $1,029 | $64 |
| Short return visit (20+ min) | 11 | $889 | $81 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 30 | $701 | $23 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $223 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $32 | $3 |
2020: 28 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 37 | $38,178 | $1,005 |
| Return visit (30+ min) | 197 | $20,812 | $88 |
| New patient visit (60+ min) | 74 | $13,786 | $186 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 44 | $11,538 | $256 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,392 | $175 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 123 | $7,376 | $27 |
| Programming of heart rhythm stimulation after drug infusion | 52 | $6,989 | $132 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 16 | $6,246 | $347 |
| External ekg recording for more than 48 hours up to 21 days | 216 | $6,228 | $28 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 16 | $6,125 | $383 |
| Telephone medical discussion with physician, 11-20 minutes | 82 | $5,921 | $70 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 215 | $5,494 | $24 |
| Telephone medical discussion with physician, 21-30 minutes | 51 | $5,038 | $97 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 82 | $4,826 | $27 |
| Critical care, first 30-74 minutes | 17 | $4,421 | $192 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 42 | $3,553 | $32 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 159 | $2,718 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,044 | $93 |
| Long return visit (40+ min) | 14 | $1,961 | $140 |
| External shock to heart to regulate heart beat | 17 | $1,714 | $101 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 146 | $1,446 | $7 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 16 | $1,336 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $1,231 | $68 |
| Ultrasound of heart, follow-up | 50 | $1,220 | $24 |
| Programming of dual lead pacemaker system | 18 | $1,188 | $66 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 44 | $1,065 | $24 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 11 | $1,006 | $23 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 11 | $966 | $88 |
2019: 33 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 61 | $58,407 | $927 |
| Return visit (30+ min) | 269 | $34,491 | $95 |
| New patient visit (60+ min) | 121 | $21,435 | $177 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 78 | $19,056 | $238 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $13,375 | $178 |
| Programming of heart rhythm stimulation after drug infusion | 87 | $11,209 | $125 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 17 | $10,008 | $589 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 22 | $9,183 | $353 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 25 | $9,156 | $366 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 12 | $7,660 | $638 |
| Critical care, first 30-74 minutes | 28 | $7,416 | $195 |
| External ekg recording for more than 48 hours up to 21 days | 238 | $6,685 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 239 | $5,930 | $24 |
| Long return visit (40+ min) | 31 | $4,119 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,561 | $94 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 306 | $3,370 | $8 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 165 | $2,931 | $16 |
| Programming of dual lead pacemaker system | 37 | $2,517 | $55 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 29 | $2,300 | $79 |
| Ultrasound of heart, follow-up | 78 | $1,995 | $23 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 23 | $1,740 | $40 |
| Programming of dual lead implantable defibrillator system | 16 | $1,477 | $67 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $1,210 | $67 |
| Short return visit (20+ min) | 17 | $1,135 | $63 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $1,132 | $23 |
| Sleep study including heart rate and breathing | 11 | $952 | $87 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 12 | $889 | $74 |
| Programming of single lead implantable defibrillator system | 11 | $805 | $57 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 17 | $751 | $27 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 29 | $711 | $24 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 15 | $630 | $13 |
| Evaluation of implantable heart and blood vessel monitoring system | 12 | $470 | $34 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 13 | $430 | $23 |
2018: 33 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 56 | $46,864 | $808 |
| Return visit (30+ min) | 206 | $28,408 | $93 |
| New patient visit (60+ min) | 113 | $20,502 | $181 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 65 | $16,346 | $244 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 75 | $13,459 | $173 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 27 | $9,634 | $344 |
| Critical care, first 30-74 minutes | 39 | $9,133 | $190 |
| Programming of heart rhythm stimulation after drug infusion | 63 | $8,746 | $135 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 18 | $8,125 | $353 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $7,411 | $93 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 11 | $7,311 | $665 |
| Long return visit (40+ min) | 45 | $5,771 | $125 |
| External ekg recording for more than 48 hours up to 21 days | 135 | $3,838 | $27 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 18 | $3,797 | $211 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 42 | $3,753 | $87 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 135 | $3,383 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 208 | $2,602 | $7 |
| Programming of dual lead pacemaker system | 39 | $2,472 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 131 | $2,223 | $16 |
| Ultrasound of heart, follow-up | 78 | $1,890 | $23 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 19 | $1,847 | $97 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 19 | $1,564 | $42 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,516 | $66 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 21 | $1,463 | $20 |
| Programming of dual lead implantable defibrillator system | 11 | $1,460 | $70 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 17 | $1,433 | $84 |
| External shock to heart to regulate heart beat | 13 | $1,297 | $100 |
| Short return visit (20+ min) | 23 | $1,163 | $51 |
| Programming of single lead implantable defibrillator system | 14 | $864 | $48 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 36 | $837 | $23 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 21 | $801 | $11 |
| Evaluation of implantable heart and blood vessel monitoring system | 15 | $656 | $31 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 13 | $491 | $26 |
2017: 31 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 47 | $37,505 | $781 |
| New patient visit (60+ min) | 112 | $20,380 | $182 |
| Return visit (30+ min) | 157 | $19,349 | $92 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 59 | $17,567 | $283 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 16 | $11,067 | $651 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $9,485 | $176 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 11 | $8,300 | $692 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 38 | $8,261 | $207 |
| Critical care, first 30-74 minutes | 35 | $8,162 | $190 |
| Programming of heart rhythm stimulation after drug infusion | 54 | $7,463 | $131 |
| Long return visit (40+ min) | 51 | $6,698 | $118 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 16 | $6,258 | $368 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $5,953 | $458 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 15 | $5,505 | $367 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $5,266 | $89 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 55 | $5,079 | $88 |
| External ekg recording for more than 48 hours up to 21 days | 106 | $2,871 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 105 | $2,511 | $23 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 22 | $2,099 | $91 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 93 | $1,904 | $16 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,889 | $86 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $1,662 | $21 |
| Programming of dual lead pacemaker system | 24 | $1,442 | $52 |
| Short return visit (20+ min) | 22 | $1,428 | $65 |
| Sleep study including heart rate and breathing | 14 | $1,240 | $89 |
| Programming of dual lead implantable defibrillator system | 12 | $1,232 | $72 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $1,034 | $57 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 12 | $902 | $12 |
| Ultrasound of heart, follow-up | 32 | $763 | $23 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 15 | $350 | $23 |
| Ultrasonic guidance for blood vessel access | 11 | $178 | $13 |
2016: 30 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 61 | $43,438 | $668 |
| New patient visit (60+ min) | 120 | $21,763 | $181 |
| Return visit (30+ min) | 138 | $19,283 | $88 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 72 | $18,527 | $247 |
| Long return visit (40+ min) | 86 | $17,489 | $129 |
| Critical care, first 30-74 minutes | 46 | $11,918 | $189 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 15 | $9,743 | $650 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $9,163 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,037 | $175 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 18 | $7,066 | $336 |
| Programming of heart rhythm stimulation after drug infusion | 51 | $7,021 | $125 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $6,403 | $427 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 23 | $6,256 | $272 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 64 | $5,527 | $79 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 24 | $5,165 | $215 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 112 | $2,559 | $16 |
| Programming of dual lead pacemaker system | 34 | $2,272 | $53 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 21 | $2,094 | $21 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 20 | $1,942 | $97 |
| External ekg recording for more than 48 hours up to 21 days | 60 | $1,697 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 60 | $1,474 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 20 | $1,146 | $57 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 21 | $1,125 | $11 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $1,090 | $61 |
| Programming of single lead implantable defibrillator system | 12 | $1,082 | $52 |
| Short return visit (20+ min) | 13 | $691 | $53 |
| Programming of dual lead pacemaker system | 11 | $418 | $35 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 18 | $389 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 26 | $196 | $7 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 18 | $177 | $8 |
2015: 31 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 62 | $45,036 | $693 |
| New patient visit (60+ min) | 130 | $26,496 | $204 |
| Long return visit (40+ min) | 122 | $22,969 | $128 |
| Critical care, first 30-74 minutes | 74 | $22,352 | $205 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 66 | $18,158 | $263 |
| Return visit (30+ min) | 109 | $16,442 | $105 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 15 | $10,233 | $682 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 23 | $8,937 | $357 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,261 | $188 |
| Programming of heart rhythm stimulation after drug infusion | 57 | $8,052 | $134 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 64 | $6,365 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $5,367 | $98 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 16 | $4,839 | $302 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 202 | $4,523 | $17 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 17 | $3,835 | $226 |
| Transitional care management services for problem of high complexity | 14 | $3,235 | $231 |
| External ekg recording for more than 48 hours up to 21 days with analysis, report, review and interpretation | 28 | $2,917 | $104 |
| External shock to heart to regulate heart beat | 19 | $2,401 | $114 |
| Implantation patient-activated heart monitoring device | 12 | $2,252 | $188 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 23 | $2,103 | $84 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 19 | $2,061 | $103 |
| Programming of dual lead pacemaker system | 23 | $1,889 | $59 |
| Programming of single lead implantable defibrillator system | 12 | $1,216 | $64 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $955 | $64 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $952 | $25 |
| Programming of single lead pacemaker system | 11 | $903 | $50 |
| External ekg recording for more than 48 hours up to 21 days | 20 | $603 | $30 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 15 | $529 | $14 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 20 | $507 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 46 | $371 | $8 |
| Imaging guidance for procedure, 60 minutes or less | 15 | $129 | $8 |
2014: 9 services
| Critical care, first 30-74 minutes | 34 | $9,772 | $195 |
| Long return visit (40+ min) | 45 | $7,503 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,041 | $180 |
| New patient visit (60+ min) | 16 | $2,911 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,573 | $93 |
| Return visit (30+ min) | 13 | $1,509 | $101 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 14 | $804 | $57 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 37 | $645 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 45 | $371 | $8 |
Medicaid work
$389 in 2022
Medicaid paid $389 for 15 billed services this clinician did in 2022, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 15 | $389 |
| 2022 | 15 | 1 | 15 | $389 |
| 2021 | 144 | 5 | 18 | $2,644 |
| 2020 | 107 | 2 | 18 | $1,577 |
| 2019 | 202 | 4 | 28 | $2,383 |
| 2018 | 98 | 1 | 29 | $1,086 |
See the largest Medicaid services in earlier years
2021
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 80 | $1,369 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 25 | $704 |
| Return visit (30+ min) | 15 | $204 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 12 | $196 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | 12 | $170 |
2020
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 61 | $1,057 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 46 | $520 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 142 | $1,417 |
| Return visit (30+ min) | 12 | $344 |
| External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | 24 | $328 |
| External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation | 24 | $294 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 98 | $1,086 |
Drugs they prescribed that Part D paid
$174,527
Pharmacies billed $174,527 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 389) in 2024. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 0%.
251 generic and 138 brand-name prescriptions · $174,527 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 99 | $119,842 | $1,211 |
| Multaq | 20 | $23,409 | $1,170 |
| Flecainide Acetate | 17 | $944 | $56 |
| Metoprolol | 59 | $879 | $15 |
| Diltiazem 24hr Er (Cd) | 38 | $723 | $19 |
See all 9 drugs
| Eliquis | 99 | $119,842 | $1,211 |
| Multaq | 20 | $23,409 | $1,170 |
| Flecainide Acetate | 17 | $944 | $56 |
| Metoprolol | 59 | $879 | $15 |
| Diltiazem 24hr Er (Cd) | 38 | $723 | $19 |
| Sotalol | 18 | $229 | $13 |
| Losartan | 20 | $156 | $8 |
| Carvedilol | 20 | $107 | $5 |
| Lisinopril | 13 | $25 | $2 |
Year by year
| 2024 | 389 | 111 | 0% (0) | 35% | $174,527 |
| 2023 | 744 | 221 | 0% (0) | None | $360,036 |
| 2022 | 1,424 | 316 | 0% (0) | 40% | $670,367 |
| 2021 | 2,073 | 380 | 0% (0) | 37% | $843,069 |
| 2020 | 1,789 | 318 | None | 35% | $665,880 |
| 2019 | 1,686 | 294 | 0% (0) | 38% | $617,830 |
| 2018 | 1,408 | 256 | None | 43% | $501,524 |
| 2017 | 1,324 | 219 | 0% (0) | 50% | $385,295 |
| 2016 | 1,412 | 216 | None | 48% | $348,953 |
| 2015 | 1,063 | 171 | 0% (0) | 49% | $212,845 |
| 2014 | 152 | 49 | None | 47% | $33,793 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Eliquis | 197 | $233,970 | $1,188 |
| Multaq | 37 | $43,805 | $1,184 |
| Dofetilide | 46 | $24,678 | $536 |
| Diltiazem 24hr Er (Cd) | 89 | $2,764 | $31 |
| Flecainide Acetate | 35 | $1,859 | $53 |
| Metoprolol | 70 | $1,593 | $23 |
| Amiodarone | 12 | $1,576 | $131 |
| Verapamil Er | 11 | $723 | $66 |
| Sotalol | 22 | $466 | $21 |
| Losartan | 35 | $461 | $13 |
| Carvedilol | 20 | $414 | $21 |
| Spironolactone | 14 | $185 | $13 |
| Doxycycline Hyclate | 12 | $76 | $6 |
| Furosemide | 16 | $70 | $4 |
2022: 22 drugs
| Eliquis | 410 | $414,879 | $1,012 |
| Multaq | 71 | $75,689 | $1,066 |
| Dofetilide | 152 | $71,129 | $468 |
| Xarelto | 34 | $47,459 | $1,396 |
| Entresto | 12 | $11,990 | $999 |
| Savaysa | 11 | $11,824 | $1,075 |
| Pradaxa | 11 | $5,385 | $490 |
| Diltiazem 24hr Er (Cd) | 125 | $3,962 | $32 |
| Flecainide Acetate | 37 | $2,315 | $63 |
| Metoprolol | 66 | $1,589 | $24 |
| Amiodarone | 47 | $1,389 | $30 |
| Spironolactone | 58 | $925 | $16 |
| Sotalol | 41 | $871 | $21 |
| Carvedilol | 48 | $770 | $16 |
| Losartan | 63 | $602 | $10 |
| Sotalol Af | 11 | $495 | $45 |
| Atorvastatin | 31 | $446 | $14 |
| Lisinopril | 13 | $252 | $19 |
| Amlodipine Besylate | 36 | $231 | $6 |
| Doxycycline Hyclate | 12 | $164 | $14 |
| Furosemide | 21 | $132 | $6 |
| Metoprolol | 13 | $104 | $8 |
2021: 23 drugs
| Eliquis | 564 | $517,871 | $918 |
| Dofetilide | 282 | $113,130 | $401 |
| Multaq | 74 | $79,586 | $1,075 |
| Xarelto | 53 | $62,797 | $1,185 |
| Pradaxa | 23 | $13,117 | $570 |
| Entresto | 15 | $11,313 | $754 |
| Savaysa | 12 | $10,408 | $867 |
| Diltiazem 24hr Er (Cd) | 196 | $6,090 | $31 |
| Amiodarone | 70 | $3,757 | $54 |
| Metoprolol | 92 | $2,891 | $31 |
| Flecainide Acetate | 39 | $2,786 | $71 |
| Sotalol | 62 | $1,477 | $24 |
| Spironolactone | 102 | $1,259 | $12 |
| Carvedilol | 81 | $1,193 | $15 |
| Sotalol Af | 23 | $981 | $43 |
| Atorvastatin | 54 | $779 | $14 |
| Losartan | 63 | $647 | $10 |
| Verapamil Er | 12 | $570 | $47 |
| Cartia Xt | 13 | $513 | $39 |
| Lisinopril | 37 | $479 | $13 |
| Amlodipine Besylate | 47 | $377 | $8 |
| Furosemide | 33 | $299 | $9 |
| Metoprolol | 15 | $159 | $11 |
2020: 20 drugs
| Eliquis | 481 | $439,406 | $914 |
| Dofetilide | 219 | $103,586 | $473 |
| Xarelto | 33 | $34,649 | $1,050 |
| Pradaxa | 38 | $24,824 | $653 |
| Multaq | 17 | $18,284 | $1,076 |
| Flecainide Acetate | 48 | $5,704 | $119 |
| Diltiazem 24hr Er (Cd) | 151 | $4,921 | $33 |
| Metoprolol | 102 | $2,876 | $28 |
| Sotalol | 53 | $2,630 | $50 |
| Amiodarone | 56 | $1,743 | $31 |
| Losartan | 79 | $1,397 | $18 |
| Carvedilol | 80 | $1,109 | $14 |
| Cartia Xt | 34 | $1,090 | $32 |
| Atorvastatin | 53 | $1,036 | $20 |
| Sotalol Af | 23 | $930 | $40 |
| Spironolactone | 67 | $875 | $13 |
| Verapamil Er | 12 | $633 | $53 |
| Amlodipine Besylate | 62 | $611 | $10 |
| Furosemide | 26 | $210 | $8 |
| Metoprolol | 20 | $199 | $10 |
2019: 22 drugs
| Eliquis | 480 | $392,837 | $818 |
| Dofetilide | 187 | $133,640 | $715 |
| Xarelto | 32 | $31,851 | $995 |
| Pradaxa | 27 | $15,707 | $582 |
| Multaq | 11 | $10,058 | $914 |
| Flecainide Acetate | 68 | $4,893 | $72 |
| Sotalol | 60 | $3,974 | $66 |
| Diltiazem 24hr Er (Cd) | 116 | $3,862 | $33 |
| Metoprolol | 95 | $3,032 | $32 |
| Cartia Xt | 43 | $1,445 | $34 |
| Amiodarone | 66 | $1,437 | $22 |
| Sotalol Af | 13 | $1,184 | $91 |
| Atorvastatin | 49 | $945 | $19 |
| Spironolactone | 51 | $868 | $17 |
| Losartan | 61 | $716 | $12 |
| Carvedilol | 57 | $516 | $9 |
| Amlodipine Besylate | 59 | $448 | $8 |
| Verapamil Er | 13 | $395 | $30 |
| Furosemide | 24 | $292 | $12 |
| Metoprolol | 17 | $171 | $10 |
| Atenolol | 11 | $99 | $9 |
| Lisinopril | 11 | $73 | $7 |
2018: 21 drugs
| Eliquis | 450 | $308,753 | $686 |
| Dofetilide | 155 | $121,756 | $786 |
| Xarelto | 25 | $26,908 | $1,076 |
| Pradaxa | 12 | $6,435 | $536 |
| Sotalol | 56 | $4,488 | $80 |
| Flecainide Acetate | 78 | $4,415 | $57 |
| Metoprolol | 94 | $3,318 | $35 |
| Diltiazem 24hr Er (Cd) | 41 | $1,403 | $34 |
| Cartia Xt | 52 | $1,252 | $24 |
| Dilt-Xr | 13 | $760 | $58 |
| Amiodarone | 32 | $760 | $24 |
| Atorvastatin | 28 | $638 | $23 |
| Carvedilol | 43 | $490 | $11 |
| Spironolactone | 46 | $476 | $10 |
| Omeprazole | 12 | $349 | $29 |
| Amlodipine Besylate | 35 | $295 | $8 |
| Losartan | 26 | $223 | $9 |
| Furosemide | 36 | $189 | $5 |
| Metoprolol | 12 | $91 | $8 |
| Simvastatin | 13 | $75 | $6 |
| Atenolol | 11 | $31 | $3 |
2017: 22 drugs
| Eliquis | 439 | $240,206 | $547 |
| Dofetilide | 141 | $94,848 | $673 |
| Xarelto | 17 | $18,461 | $1,086 |
| Flecainide Acetate | 49 | $3,847 | $79 |
| Metoprolol | 127 | $3,584 | $28 |
| Sotalol | 80 | $2,108 | $26 |
| Sotalol Af | 22 | $1,129 | $51 |
| Diltiazem 24hr Er | 42 | $970 | $23 |
| Amiodarone | 34 | $969 | $29 |
| Atorvastatin | 38 | $809 | $21 |
| Omeprazole | 22 | $460 | $21 |
| Cartia Xt | 19 | $450 | $24 |
| Carvedilol | 35 | $366 | $10 |
| Potassium Chloride | 13 | $222 | $17 |
| Spironolactone | 31 | $188 | $6 |
| Losartan | 11 | $156 | $14 |
| Furosemide | 29 | $123 | $4 |
| Simvastatin | 16 | $116 | $7 |
| Lisinopril | 15 | $94 | $6 |
| Metoprolol | 13 | $86 | $7 |
| Clopidogrel | 11 | $67 | $6 |
| Amlodipine Besylate | 17 | $56 | $3 |
2016: 23 drugs
| Eliquis | 411 | $208,041 | $506 |
| Tikosyn | 54 | $59,490 | $1,102 |
| Dofetilide | 34 | $25,608 | $753 |
| Xarelto | 24 | $18,417 | $767 |
| Pradaxa | 14 | $7,222 | $516 |
| Metoprolol | 191 | $6,215 | $33 |
| Flecainide Acetate | 71 | $2,559 | $36 |
| Sotalol | 83 | $1,399 | $17 |
| Sotalol Af | 32 | $1,386 | $43 |
| Omeprazole | 76 | $1,114 | $15 |
| Cartia Xt | 28 | $1,019 | $36 |
| Diltiazem 24hr Er | 35 | $1,007 | $29 |
| Atorvastatin | 23 | $567 | $25 |
| Spironolactone | 24 | $403 | $17 |
| Carvedilol | 22 | $290 | $13 |
| Metoprolol | 31 | $227 | $7 |
| Lisinopril | 16 | $205 | $13 |
| Amiodarone | 15 | $200 | $13 |
| Furosemide | 35 | $172 | $5 |
| Clopidogrel | 13 | $127 | $10 |
| Simvastatin | 17 | $93 | $5 |
| Amlodipine Besylate | 20 | $81 | $4 |
| Calcitriol | 11 | $77 | $7 |
2015: 18 drugs
| Eliquis | 320 | $142,693 | $446 |
| Tikosyn | 39 | $20,320 | $521 |
| Xarelto | 19 | $9,546 | $502 |
| Multaq | 14 | $7,403 | $529 |
| Metoprolol | 122 | $4,902 | $40 |
| Flecainide Acetate | 91 | $3,551 | $39 |
| Crestor | 11 | $2,410 | $219 |
| Cartia Xt | 28 | $1,339 | $48 |
| Omeprazole | 75 | $873 | $12 |
| Diltiazem 24hr Er | 27 | $627 | $23 |
| Sotalol | 40 | $586 | $15 |
| Atorvastatin | 14 | $240 | $17 |
| Amiodarone | 13 | $215 | $17 |
| Lisinopril | 20 | $154 | $8 |
| Furosemide | 37 | $143 | $4 |
| Spironolactone | 17 | $112 | $7 |
| Carvedilol | 11 | $111 | $10 |
| Simvastatin | 11 | $29 | $3 |
2014: 3 drugs
| Eliquis | 52 | $23,308 | $448 |
| Metoprolol | 13 | $640 | $49 |
| Flecainide Acetate | 12 | $558 | $47 |
Money from drug and device companies
$2,616 in 2025
| 2025 | 5 | 23 | $1,100 | $2,616 |
| 2024 | 3 | 20 | None | $2,343 |
| 2023 | 7 | 39 | $3,600 | $14,685 |
| 2022 | 5 | 35 | None | $3,475 |
| 2021 | 3 | 22 | None | $1,633 |
| 2020 | 1 | 1 | None | $86 |
| 2019 | 4 | 14 | None | $1,210 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Zywie | None | $1,100 | 1 payment
|
| Abbott Laboratories | Ensite | $896 | 12 payments
|
| AtriCure | Epi-Sense Guided Coagulation System With Visitrax | $533 | 7 payments
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $54 | 2 payments
|
| Boston Scientific | Farapulse | $33 | 1 payment
|
See all 23 published payments
| Abbott Laboratories | Meals · 2025-12-28 | Na | $24 |
| Abbott Laboratories | Meals · 2025-12-26 | Ensite | $70 |
| Baxter Healthcare | Meals · 2025-11-25 | Hillrom - Carnation Ambulatory Monitor | $21 |
| AtriCure | Meals · 2025-09-13 | Epi-Sense Guided Coagulation System With Visitrax | $103 |
| AtriCure | Meals · 2025-09-13 | Epi-Sense Guided Coagulation System With Visitrax | $53 |
| AtriCure | Meals · 2025-09-13 | Epi-Sense Guided Coagulation System With Visitrax | $89 |
| AtriCure | Meals · 2025-09-12 | Epi-Sense Guided Coagulation System With Visitrax | $175 |
| Baxter Healthcare | Meals · 2025-08-22 | Hillrom - Carnation Ambulatory Monitor | $33 |
| Abbott Laboratories | Travel · 2025-08-14 | Tacticath Ablation Catheter, Sensor Enabled | $88 |
| Abbott Laboratories | Travel · 2025-08-14 | Tacticath Ablation Catheter, Sensor Enabled | $9 |
| Abbott Laboratories | Meals · 2025-06-12 | Ensite Precision | $25 |
| AtriCure | Meals · 2025-06-09 | Epi-Sense Guided Coagulation System With Visitrax | $47 |
| Boston Scientific | Meals · 2025-06-02 | Farapulse | $33 |
| Zywie | Consulting · 2025-05-28 | None | $1,100 |
| Abbott Laboratories | Meals · 2025-05-06 | Ensite | $172 |
| Abbott Laboratories | Meals · 2025-05-06 | Ensite | $163 |
| AtriCure | Meals · 2025-05-01 | Epi-Sense Guided Coagulation System With Visitrax | $24 |
| AtriCure | Meals · 2025-04-25 | Epi-Sense Guided Coagulation System With Visitrax | $42 |
| Abbott Laboratories | Meals · 2025-04-17 | None | $113 |
| Abbott Laboratories | Meals · 2025-04-14 | Agilis | $24 |
| Abbott Laboratories | Meals · 2025-04-14 | Agilis | $4 |
| Abbott Laboratories | Meals · 2025-02-20 | Ensite | $180 |
| Abbott Laboratories | Meals · 2025-01-10 | Workmate Claris | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,343
| Atricure | Epi-Sense Guided Coagulation System With Visitrax | $1,258 | 9 payments
|
| Abbott Laboratories | Ensite | $1,030 | 9 payments
|
| Boston Scientific | None | $55 | 2 payments
|
2023: $14,685
| Biosense Webster | Carto 3 | $11,105 | 13 payments
|
| Atricure | Epi-Sense Guided Coagulation System With Visitrax | $1,629 | 10 payments
|
| Abbott Laboratories | Ensite Precision | $1,526 | 11 payments
|
| Medtronic | Selectsecure | $278 | 2 payments
|
| Boston Scientific | Watchman Flx | $111 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $31 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $6 | 1 payment
|
2022: $3,475
| Abbott Laboratories | Ensite Precision | $1,923 | 20 payments
|
| AtriCure | Epi-Sense Guided Coagulation System With Visitrax | $1,243 | 8 payments
|
| Medtronic | Micra | $134 | 4 payments
|
| Boston Scientific | General - Ep | $100 | 1 payment
|
| Biosense Webster | Carto 3 | $75 | 2 payments
|
2021: $1,633
| Abbott Laboratories | Ensite Precision Cardiac Mapping System | $1,247 | 16 payments
|
| Atricure | Epi-Sense Guided Coagulation System With Visitrax | $227 | 5 payments
|
| Biotronik | Edora | $159 | 1 payment
|
2020: $86
| Medtronic Vascular | Reveal Linq | $86 | 1 payment
|
2019: $1,210
| Abbott Laboratories | Ensite Cardiac Mapping System | $500 | 8 payments
|
| Biotronik | None | $462 | 3 payments
|
| Medtronic Vascular | None | $146 | 1 payment
|
| Boston Scientific | General Therapies | $101 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kardium Inc. · Kardium Pulsar Doc-189367 · 2024 | Their institution | $221,659 |
| AtriCure, Inc. · Hybrid Convergent of Epicardial and Endocardial Rf Ablation for the Treatment of Symptomatic Longstanding Persistent Af · 2025 | Their institution | $142,883 |
| BOSTON SCIENTIFIC CORPORATION · Advent · 2022 | Their institution | $120,360 |
| Abbott Laboratories · Volt-Af Ide Clinical Study · 2024 | Their institution | $111,401 |
| Kardium Inc. · Kardium Pulsar Doc-189367 · 2025 | Their institution | $87,470 |
| Abbott Laboratories · Nct06223789--Volt-Af Ide Clinical Study · 2025 | Their institution | $83,513 |
| BOSTON SCIENTIFIC CORPORATION · Advent · 2021 | Their institution | $75,917 |
| Abbott Laboratories · Volt-Af Ide · 2024 | Their institution | $51,329 |
| BOSTON SCIENTIFIC CORPORATION · Option · 2020 | Their institution | $48,063 |
| Boston Scientific Corporation · Option · 2021 | Their institution | $35,659 |
| Boston Scientific Corporation · Advent Lto · 2025 | Their institution | $32,493 |
| Biosense Webster, Inc. · Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bwi Ire Ablation System · 2022 | Their institution | $27,000 |
| Biosense Webster, Inc. · Investigator Initiated Randomized Controlled Trial Comparing Two Radiofrequency Ablation Strategies in Patients With Persistent Atrial Fibrillation · 2020 | Their institution | $25,000 |
| BOSTON SCIENTIFIC CORPORATION · Option · 2022 | Their institution | $17,703 |
| Boston Scientific Corporation · Option · 2023 | Their institution | $16,439 |
| Abbott Laboratories · Lsi (Lesion Index) Workflow Post-Market Observational Study · 2020 | Their institution | $14,775 |
| Abbott Laboratories · Safety and Effectiveness of Tactiflex Ablation Catheter, Sensor Enabled (Tactiflex Se) for the Treatment of Drug Refractory, Symptomatic, Paroxysmal Atrial Fibrillation · 2020 | Their institution | $11,505 |
| Abbott Laboratories · Prospective, Multicenter, Post-Market, Single-Arm, Observational Study · 2019 | Their institution | $10,000 |
| Boston Scientific Corporation · Advent · 2023 | Their institution | $9,152 |
| Abbott Laboratories · His Bundle Pacing Pacemaker Mapping Registry · 2021 | Their institution | $9,150 |
| Biosense Webster, Inc. · Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bwi Ire Ablation System · 2024 | Their institution | $7,607 |
| Boston Scientific Corporation · Option · 2024 | Their institution | $6,109 |
| Biosense Webster, Inc. · Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bwi Ire Ablation System · 2023 | Their institution | $4,500 |
| Abbott Laboratories · Prospective, Multicenter, Post-Market, Single-Arm, Observational Study · 2021 | Their institution | $3,838 |
| Abbott Laboratories · Physiologic Pacing Registry · 2022 | Their institution | $1,850 |
| Abbott Laboratories · Safety and Effectiveness of Tactiflex Ablation Catheter, Sensor Enabled (Tactiflex Se) for the Treatment of Drug Refractory, Symptomatic, Paroxysmal Atrial Fibrillation · 2022 | Their institution | $1,550 |
| Abbott Laboratories · Lsi (Lesion Index) Workflow Post-Market Observational Study · 2022 | Their institution | $1,400 |
| Boston Scientific Corporation · Option · 2025 | Their institution | $1,324 |
| Abbott Laboratories · Tactiflex Ide · 2021 | Their institution | $650 |
| Abbott Laboratories · Safety and Effectiveness of the Tactiflex(Tm) Ablation Catheter, Sensor Enabled(Tm) (Tactiflex Se) for Treating Drug-Refractory, Symptomatic Atrial Fibrillation · 2023 | Their institution | $500 |
| Abbott Laboratories · Physiologic Pacing Registry · 2020 | Their institution | $75 |
Professional record
- NPI
- 1740460088
- Licence
- CA A100919California A100919: Current · expires 2027-06-30
- Trained
- University of California, Geffen School of Medicine, 2006
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-11-03
- NPI last updated
- 2022-02-18
- NPI record certified
- 2022-02-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1100 Van Ness Ave, San Francisco, CA, 94109 · 34 Mark West Springs Rd, Santa Rosa, CA, 95403